Key Details
Price
$30.05Annual ROE
-15.62%Beta
0.77Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 6, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
The average of price targets set by Wall Street analysts indicates a potential upside of 113.1% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
NBBK, OMCL, ZIM, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on December 12, 2024.
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earlier-line patients and combinations 3Q 2024 earnings per share (EPS) of $0.17 compared to 3Q 2023 EPS of $0.02 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
FAQ
- What is the ticker symbol for Immunocore Holdings?
- Does Immunocore Holdings pay dividends?
- What sector is Immunocore Holdings in?
- What industry is Immunocore Holdings in?
- What country is Immunocore Holdings based in?
- When did Immunocore Holdings go public?
- Is Immunocore Holdings in the S&P 500?
- Is Immunocore Holdings in the NASDAQ 100?
- Is Immunocore Holdings in the Dow Jones?
- When was Immunocore Holdings's last earnings report?
- When does Immunocore Holdings report earnings?
- Should I buy Immunocore Holdings stock now?